Sorriso Prescription drugs, a Salt Lake Metropolis, UT-based firm targeted on remodeling anti-inflammatory antibody remedy, closed on a $31m Collection A financing.
The spherical was co-led by New Enterprise Associates (NEA), and Arix Bioscience plc. At the side of the financing, Ed Mathers, common companion at NEA, and Mark Chin, managing director at Arix Bioscience, joined Sorriso’s board of administrators.
The corporate intends to make use of the funds to advance its pipeline of novel oral antibodies to handle unmet wants in immune- mediated ailments.
Led by Ciara Kennedy, president, and CEO, Sorriso Prescription drugs is a biotechnology firm advancing a pipeline of disease-modifying antibodies for the remedy of inflammatory illness, together with Crohn’s illness and ulcerative colitis. The platform generates potent antibodies that may be delivered orally and are designed to take care of exercise all through the intestinal system. The lead program is SOR102, in improvement for the remedy of inflammatory bowel illness (IBD). SOR102 concurrently inhibits TNFa and IL-23, two clinically validated drivers of IBD. This distinctive method combines the medical affect of injectable antibody therapeutics with the advantages of oral administration, leading to focused exercise, negligible systemic publicity, and minimal immunogenicity.